<SEC-DOCUMENT>0001104659-21-047595.txt : 20210615
<SEC-HEADER>0001104659-21-047595.hdr.sgml : 20210615
<ACCEPTANCE-DATETIME>20210407163922
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-21-047595
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HighCape Capital Acquisition Corp.
		CENTRAL INDEX KEY:			0001816431
		STANDARD INDUSTRIAL CLASSIFICATION:	MEASURING & CONTROLLING DEVICES, NEC [3829]
		IRS NUMBER:				851388175
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		530 OLD WHITFIELD STREET
		CITY:			GUILFORD
		STATE:			CT
		ZIP:			06437
		BUSINESS PHONE:		(203) 458-7100

	MAIL ADDRESS:	
		STREET 1:		530 OLD WHITFIELD STREET
		CITY:			GUILFORD
		STATE:			CT
		ZIP:			06437

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HighCape Capital Acquisition Corp.
		DATE OF NAME CHANGE:	20200629
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="tm217673d9_correspimg001.jpg" ALT="" STYLE="width: 188px; height: 24px"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">April 7, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA EDGAR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission<BR>
Division of Corporation Finance<BR>
Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street NE<BR>
Washington, D.C. 20549</P>
</TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm217673d9_correspimg002.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">Attn:</TD><TD>Franklin Wyman<BR>
Al Pavot<BR>
Jason Drory<BR>
Christine Westbrook</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>Re:</B></TD><TD><B>HighCape Capital Acquisition Corp.<BR>
Registration Statement on Form S-4<BR>
Filed March 1, 2021<BR>
File No. 333-253691</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of our client, HighCape
Capital Acquisition Corp., a Delaware corporation (the &ldquo;Company&rdquo;), we are writing to submit the Company&rsquo;s responses
to the comments of the staff of the Division of Corporation Finance of the United States Securities and Exchange Commission (the &ldquo;Staff&rdquo;)
with respect to the above-referenced registration statement on Form S-4 filed on March 1, 2021 (the &ldquo;Registration Statement&rdquo;),
contained in the Staff&rsquo;s letter dated March 26, 2021 (the &ldquo;Comment Letter&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has filed via
EDGAR its first amended Registration Statement on Form S-4 (the &ldquo;First Amended Registration Statement&rdquo;), which reflects the
Company&rsquo;s responses to the comments received by the Staff and certain updated information. For ease of reference, each comment contained
in the Comment Letter is printed below in bold and is followed by the Company&rsquo;s response. All page references in the responses set
forth below refer to page numbers in the First Amended Registration Statement. Capitalized terms used but not defined herein have the
meanings set forth in the First Amended Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Registration Statement on Form S-4 filed March
1, 2021</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Certain Defined Terms, page 2</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Although we do not object to the inclusion of the glossary, please revise the text of the prospectus
to explain these terms where first used. For example only, we note that &quot;Closing Date&quot; and &quot;HighCape Party&quot; are not
defined at first use.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to
the Staff&rsquo;s comment, the Company has revised the text of the proxy statement/prospectus included in the First Amended
Registration Statement to define terms where first used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Questions and Answers About the Business Combination
and the Special Meeting, page 8</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm217673d9_correspimg001.jpg" ALT="" STYLE="width: 188px; height: 24px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United
States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 7, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Please expand your disclosure under an appropriate heading to highlight that you did not obtain a fairness
opinion from a financial advisor regarding the merger consideration.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to
the Staff&rsquo;s comment, the Company has expanded its disclosure on page 15 of the First Amended Registration Statement to state,
under the heading &ldquo;<I>Did HighCape obtain a fairness opinion from a financial advisor in deciding whether to pursue the
Business Combination with Quantum-Si</I>&rdquo; that it did not obtain a fairness opinion from a financial advisor regarding the
merger consideration. The Company also inserted a corresponding risk factor on page 84 of  the First Amended
Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Simplified Post-Combination Structure, page
25</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Please revise this chart to depict the voting percentage interests of the various equity holders in
HighCape and the combined company and identify the entities that will control the combined company.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company has revised the chart on page 25 of the First Amended Registration Statement to depict the voting percentage
interests of the various equity holders in the Company and the combined company based on the assumptions set forth in the First Amended Registration
Statement and identify the entities that will control the combined
company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>HighCape's Board of Directors' Reasons for
the Approval of the Business Combination, page 28</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>4.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure on page 33 that your estimated transaction fees and expenses are $24 million.
Please revise your disclosure here to quantify the anticipated &quot;substantial transaction expenses&quot; in connection with the business
combination.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to
the Staff&rsquo;s comment, the Company has revised the disclosure on pages 34 and 114 of the First Amended Registration Statement
to quantify the anticipated transaction expenses in connection with the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Conditions to the Completion of the Business
Combination, page 29</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Please amend your disclosure to identify each condition that is subject to being waived. Please make
conforming changes to your Conditions to Closing of the Business Combination discussion beginning on page 117.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company has revised its disclosure on page 29 of the First Amended Registration Statement to identify the conditions
to the completion of the Business Combination that are subject to being waived. The Company has made corresponding revisions to the Conditions
to Closing of the Business Combination on pages 121 and 122 of the First Amended Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Interests of HighCape's Directors and Officers
in the Business Combination, page 31</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>6.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure on page 165 that founder shares were transferred to each of David Colpman,
Antony Loebel and Robert Taub, each of whom serves as a director of HighCape. In addition to disclosing the transfer, please include additional
disclosure here and on page 110 explaining that your directors may have a conflict of interest in determining to recommend the business
combination as a result of their receipt of founder shares.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to
the Staff&rsquo;s comment, the Company has supplemented its disclosure on pages 31, 32 and 113 of the First Amended Registration
Statement explaining that our directors may have a conflict of interest in determining to recommend the Business Combination as a
result of their receipt of founder shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right"><IMG SRC="tm217673d9_correspimg001.jpg" ALT="" STYLE="width: 188px; height: 24px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United
States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 7, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt"><B>7.</B></TD><TD STYLE="text-align: justify"><B>Please quantify the out-of-pocket expenses incurred by your Sponsor, executive officers, directors,
and their respective affiliates as of a recent practicable date.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><U>Response</U>:
In response to the Staff&rsquo;s comment, the Company has revised its disclosure on pages 32, 80, 114, 176 and 268 of the First
Amended Registration Statement to quantify the out-of-pocket expenses incurred by the Sponsor, executive officers, directors and
their respective affiliates as of March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Summary of Risk Factors, page 34</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>8.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure on page 90 that you will be a &quot;controlled company&quot; and that Dr. Rothberg
will hold over 80.5% of the voting power of New Quantum-Si&rsquo;s capital stock pursuant to his holding of Class B common stock. Please
add appropriate disclosure in the summary risk factors disclosing that Dr. Rothberg will hold significant voting control of New Quantum-Si.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to
the Staff&rsquo;s comment, the Company has expanded its disclosure in the summary risk factors on page 35 of the First
Amended Registration Statement to disclose that Dr. Rothberg will hold significant voting control of New Quantum-Si.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Risk Factors Relating to HighCape and the Business
Combination</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The dual class structure of New Quantum-Si
common stock will have the effect of concentrating voting power with New Quantum-Si's Chairman..., page 90</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Please expand this risk factor to disclose if future issuances of high-vote shares may be dilutive
to low-vote shareholders.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company has expanded this risk factor on page 91 of the First Amended Registration Statement to disclose that
future issuances of high-vote shares may be dilutive to low-vote shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Background of the Business Combination, page
102</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>10.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure that HighCape reviewed over 40 business combination opportunities and entered
into nondisclosure agreements with 15 companies. Please expand your disclosure to briefly discuss why such other opportunities were not
pursued.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company has expanded its disclosure on page 103 of the First Amended Registration Statement to discuss why
the Company did not pursue the other business combination opportunities reviewed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>11.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure that you reached out to Dr. Rothberg in October 2020 to inquire whether HighCape
could start discussions with any of the 4Catalyzer Corporation (&ldquo;4Catalyzer&rdquo;) companies. In addition, we note that 4Catalyzer
has multiple portfolio companies. Please expand your disclosure to discuss how you arrived at selecting Quantum-Si.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company has expanded its disclosure on page 104 of the First Amended Registration Statement to discuss how
the Company decided to pursue a business combination with Quantum-Si in lieu of the other 4Catalyzer portfolio companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right"><IMG SRC="tm217673d9_correspimg001.jpg" ALT="" STYLE="width: 188px; height: 24px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United
States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 7, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>12.</B></TD><TD STYLE="text-align: justify"><B>Please indicate how the combined company's super-voting corporate governance structure compares to
Quantum-Si's corporate governance structure. For example, disclose whether Dr. Rothberg will have more votes or other rights in the combined
company than he currently has in Quantum-Si.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company has revised its disclosure on page 106 of the First Amended Registration Statement to indicate how
the combined company's super-voting corporate governance structure compares to Quantum-Si's corporate governance structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>13.</B></TD><TD STYLE="text-align: justify"><B>Please revise to clarify how the transaction structure and consideration evolved during the negotiations
between the parties, including proposals and counter-proposals made during the course of those negotiations. For example, please revise
to discuss the negotiations regarding the valuation, structure, exchange ratio and the other material terms from the draft letter of intent
delivered on December 31, 2020 until execution of the Business Combination Agreement. To the extent the valuation was changed please revise
to disclose such change along with the reasons for such change.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to
the Staff&rsquo;s comment, the Company has expanded its disclosure on page 105 of the First Amended Registration Statement to
clarify how the transaction structure and proposed consideration evolved during the negotiations between the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>14.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure that HighCape received a valuation presentation from J.P. Morgan, which reviewed
enterprise values of select publicly traded companies. On page 108 you state that the HighCape Board did not seek a third-party valuation.
Please revise your disclosure to clarify the role of J.P. Morgan and its valuation presentation in the Board&rsquo;s consideration of
the terms of the Business Combination. Additionally, please disclose the criteria used by management to identify public companies that
management considered comparable on the basis such companies operate in the high-growth life sciences tools sector or have disruptive
technologies, as referenced on page 108.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company has revised its disclosure on pages 106 and 110 of the First Amended Registration Statement to clarify
the role J.P. Morgan and the criteria used by management to identify public companies that management considered comparable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Certain Projected Financial Information of
Quantum-Si, page 108</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>15.</B></TD><TD STYLE="text-align: justify"><B>The risk factors on pages 45-46 reference the expectation that substantial costs will be incurred to
commercialize, market and develop products. Presumably these costs will be required in order to generate the annual future revenue amounts
that are disclosed here and were provided to High Cape's Board. If you believe that these projected revenues can be generated without
having to incur any marketing, research, development, management, or other operating costs then please disclose that assumption and any
reasonable basis for that assumption. Otherwise, please expand your disclosure to present the projected operating expenses and projected
income for each period. Further, please expand your discussion to include a description and quantification of the significant assumptions
underlying the magnitude and growth in revenue and gross margin from 2022 through 2025, as reflected in your projections for Quantum Si.
At a minimum, disclose the sales volumes and per unit sales prices that support the revenue projections, as well as the basis for your
projected per unit cost of sales. In addition, include a discussion of the factors that you considered in determining that these assumptions
were reasonable. Refer to the relevant guidance in Item 10(b) of Regulation S-K.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to
the Staff&rsquo;s comment, the Company, after consultation with Quantum-Si, advises the Staff that the number of devices projected
to be sold each year is confidential and commercially sensitive and is not required to be disclosed under applicable SEC rules and
regulations nor is it necessary to enable investors to assess the current or prospective business, financial condition or results of
operations of the combined company; none of this confidential information has been disclosed to the public and the disclosure of such confidential information is not necessary
for the protection of investors. The Company has, however, revised the disclosure on page 111 of the First Amended Registration
Statement to provide additional information with respect to projected operating expenses and income and to quantify certain
significant assumptions underlying the projected magnitude and growth in revenue and gross margin. In response to the Staff&rsquo;s
comment, the Company has also revised the disclosure on page 111 of the First Amended Registration Statement to discuss the factors
considered in determining that the assumptions were reasonable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right"><IMG SRC="tm217673d9_correspimg001.jpg" ALT="" STYLE="width: 188px; height: 24px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United
States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 7, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Business of New Quantum-Si</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Overview, page 177</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>16.</B></TD><TD STYLE="text-align: justify"><B>Please clarify what you mean when you state &quot;Next Generation Protein Sequencing.&quot;</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company, after consultation with Quantum-Si, has revised the disclosure on pages 182 and 213 of the First Amended
Registration Statement to clarify the meaning of &ldquo;Next Generation Protein Sequencing.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>17.</B></TD><TD STYLE="text-align: justify"><B>We note your risk factor disclosure on page 47 where you state Quantum-Si has &quot;a three phase launch
plan for commercialization, which includes a collaboration phase, an early access limited release phase and a broad commercial availability
phase.&quot; In addition, we note your disclosure on page 107 where you state the Board considered &quot;Quantum-Si&rsquo;s ability to
demonstrate the value of its technology to existing and potential users&quot; as a positive factor for the Business Combination. Please
update your disclosure here and elsewhere in the registration statement as applicable to describe material details on the &quot;collaboration
phase,&quot; including providing additional details on Quantum-Si's &quot;existing&quot; users. To the extent a part of your platform
it is not fully developed, please revise your disclosure to clearly describe the current status of each of your planned adjacent products.
For example only, it appears you are still &quot;developing [y]our cloud-based platform&quot; based on your disclosure on page 189. Additionally,
where you state on page 178 that you &quot;intend to follow a systematic and phased approach to successfully launch and commercialize
[your] platform in 2022,&quot; please revise to clarify if such anticipated timeline refers to your commercializing research use only
products for non-diagnostic and non-clinical purposes.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company, after consultation with Quantum-Si, has revised the disclosure on pages 48, 49, 52, 109, 182,
183, 195, 197, 198 and 213 of the First Amended Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>18.</B></TD><TD STYLE="text-align: justify"><B>We note that you describe your detection platform and Next Generation Protein Sequencing as being able
to &quot;unlock deep biological information...at a speed and scale that is not available today.&quot; Please revise your disclosure to
explain the basis for this statement.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company, after consultation with Quantum-Si, has revised the disclosure on pages 182 and 213 of the First Amended
Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Our Competitive Strengths, page 189</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>19.</B></TD><TD STYLE="text-align: justify"><B>Please provide us the basis for your statement that you have a &ldquo;highly attractive business model&rdquo;
and &quot;[d]eep and expanding scientific validation&quot; given your current, pre- commercial stage of development.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company, after consultation with Quantum-Si, has revised the disclosure on page 195 of the First Amended Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Competition, page 195</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm217673d9_correspimg001.jpg" ALT="" STYLE="width: 188px; height: 24px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United
States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 7, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>20.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure regarding various competitors on page 56. Please revise your disclosure here
to identify specific competitors. In addition, we note your statement that, &quot;[w]e believe that we will be the first to offer a NPGS
platform.&quot; Please provide your basis for this statement.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: In response to the
Staff&rsquo;s comment, the Company, after consultation with Quantum-Si, has revised the disclosure on pages 200 and 201 of the First Amended
Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Licenses related to certain intellectual property,
page 215</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>21.</B></TD><TD STYLE="text-align: justify"><B>We note your risk factor disclosure on page 74 where you state that, &quot;Quantum-Si&rsquo;s current
license agreements impose, and future agreements may impose, various diligence, commercialization, milestone payment, royalty, insurance
and other obligations on it and require it to meet development timelines, or to exercise commercially reasonable efforts to develop and
commercialize licensed products, in order to maintain the licenses.&quot; Please describe the material terms of each license agreement
related to intellectual property used in your products. Please also file the agreements as exhibits to the registration statement or explain
to us why they are not required to be filed. The description of each agreement should include (i) the royalty rate, or a range no greater
than 10 percentage points per tier; (ii) when the royalty provisions expire; (iii) milestone payments; (iv) development timeline obligations;
and (v) term and termination provisions.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: The Company acknowledges
the Staff&rsquo;s comment. After consultation with Quantum-Si, the Company advises the Staff that it and Quantum-Si have concluded that
the license agreements referenced in the risk factor disclosure on page 75 of the First Amended Registration Statement are not material
to Quantum-Si&rsquo;s business and are not required to be filed as exhibits to, and described in, the Registration Statement. The Company,
after consultation with Quantum-Si, advises the Staff that it and Quantum-Si have concluded the license agreements are not material agreements
of the type specified under Item 601(b)(10) of Regulation S-K because they are agreements that ordinarily accompany the type of business
conducted by Quantum-Si. Additionally, because Quantum-Si&rsquo;s intellectual property portfolio is substantially internally developed,
Quantum-Si does not substantially depend on the licenses to commercialize its products or technologies. To the extent that Quantum-Si
does use the licensed technology, Quantum-Si believes it can be replaced with technology from other sources or internally developed solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Technology and Services Exchange Agreements
and License Agreements, page 265</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>22.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure Quantum-Si has entered into certain license agreements, including agreements
with Protein Evolution, Inc. and Tesseract Health, Inc. Please revise your disclosure to describe (i) when the royalty provisions expire
and (ii) term and termination provisions. In addition, please file the agreements as exhibits to the registration statement or explain
to us why they are not required to be filed.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Response</U>: The Company acknowledges
the Staff&rsquo;s comment. After consultation with Quantum-Si, the Company advises the Staff that it and Quantum-Si believe that the license
agreements between Quantum-Si and certain of the participant companies in the Technology and Services Exchange Agreement (the &ldquo;License
Agreements&rdquo;) are not material to Quantum-Si&rsquo;s business and are not required to be filed as exhibits to the Registration Statement
under Item 601 of Regulation S-K.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right"><IMG SRC="tm217673d9_correspimg001.jpg" ALT="" STYLE="width: 188px; height: 24px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United
States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 7, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The fields of use for which
licenses have been granted under the License Agreements are included in the disclosure regarding the License Agreements in the First
Amended Registration Statement, and consist of: (i) &nbsp;the detection of COVID-19 (and other viruses, pathogens and/or components
thereof including without limitation nucleic acids that might be useful for understanding COVID-19, including controls for correct
application) using a risk assessment assay that performs, without an electronic instrument (except for a small heater and/or
fluorescent readout),&nbsp;in an at-home or personal use environment, and/or without the assistance of a health care provider or
laboratory professional; (ii) drug discovery, drug development, and drug commercialization (but excluding biological sequencing and
protein design using &ldquo;intelligent&rdquo; evolution); (iii) ophthalmic imaging and/or measuring, including but not limited to
associated point-of-care diagnostics, including but not limited to fluorescence lifetime imaging (FLI) and/or optical coherence
tomography (OCT), and time-of-flight sensors, including but not limited to range finding and 3D imaging; and (iv) protein design
using directed evolution (the &ldquo;PEI Field&rdquo;) and  for the concentration,
purification, analysis and/or other manipulation of biomolecules solely within the PEI Field. None of these fields of use is within
the current or potential scope of Quantum-Si&rsquo;s business, and Quantum-Si does not expect that royalties to be paid to the
combined company under the License Agreements, if any, will be material in amount or significance. Therefore, Quantum-Si and the
Company have concluded that the License Agreements are not material to Quantum-Si or the combined company, and thus the Company does
not believe that additional disclosure of terms of the License Agreements is required, or that the License Agreements are required
to be filed as exhibits to the Registration Statement. The Company has further revised the disclosure on pages 271 and 272 of the
First Amended Registration Statement to further clarify the scope of the fields of use of these agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please do not hesitate to
contact David Johansen at (212) 819-8509 of White &amp; Case LLP with any questions or comments regarding this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Best regards,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ White &amp; Case LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">White &amp; Case LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">cc:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kevin Rakin and Matt Zuga, HighCape Capital Acquisition Corp.</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm217673d9_correspimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm217673d9_correspimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$$17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %)A:F5N9')A
M;BP@2V%A<G1H:0    60 P "    %   $*R0!  "    %   $,"2D0 "
M SDP  "2D@ "     SDP  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm217673d9_correspimg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm217673d9_correspimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F +@# 2(  A$! Q$!_\0
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A8JW]?\ FHHHJ30**** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
